Prostate Cancer Clinical Trial
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
The purpose of this study is to find out how best to detect clinically significant lesions of prostate cancer by using micro-ultrasound technology (ExactVu) and by multiparametric magnetic-resonance imaging (mpMRI).
This is a pilot clinical trial with 30 patients with either: 1) suspected prostate cancer (based on elevated PSA or abnormal digital rectal exam (DRE), or 2) known low-risk prostate cancer being managed with active surveillance.
Enrolled patients will undergo MRI fusion biopsy and standard-template 12 core TRUS biopsy as the standard-of-care. Patients will also undergo micro-ultrasound evaluation and targeted biopsy if lesions are identified. Detection rates of clinically significant lesions by ExactVu and by MRI will be compared.
Patients scheduled to undergo biopsy and with one of the following:
Men with suspicion of prostate cancer
Men on active surveillance
Age ≥18 
Have available multiparametric prostate MRI
Able to provide written, informed consent
No significant medical illness which in the opinion of the Investigator would preclude entry to study procedures
Be willing and able to comply with scheduled visits
Previously confirmed prostate cancer diagnosis with Grade Group >= 2
Unable to undergo prostate biopsy
Prostate MRI unable to be evaluated using the PI-RADS v2 criteria
Men with contraindication for MRI or a prostate biopsy
Prostate biopsy within 8 weeks prior to mpMRI.
Any history of prostate treatment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.